Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

被引：0
|
作者：
Isaza, Nicolas
Calvachi, Paola
Raber, Inbar
Shen, Changyu
Gavin, Michael C.
Garan, A. Reshad
Bellows, Brandon K.
Kazi, Dhruv S.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A15981
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [2] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [3] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [4] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [5] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [6] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023,
  • [7] COMPARATIVE COST EFFECTIVENESS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    Gravlee, E.
    Prajapati, P.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S409 - S410
  • [8] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Ghader Mohammadnezhad
    Behniya Azadmehr
    Mehdi Mirheidari
    Nazila Yousefi
    [J]. Cost Effectiveness and Resource Allocation, 20
  • [9] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [10] Cost-effectiveness of add-on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
    Abushanab, Dina
    Chbib, Salma
    Kaddoura, Rasha
    Al Hail, Moza
    Rouf, Palli Valappila Abdul
    El Kassem, Wessam
    Shah, Jassim
    Nair, Ramesh Kumar Ravindran
    Al-Badriyeh, Daoud
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 404 - 417
12345